Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.71 USD

28.71
28,634,708

-0.17 (-0.59%)

Updated Aug 15, 2024 04:01 PM ET

Pre-Market: $28.69 -0.02 (-0.07%) 8:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Compared to Estimates, Pfizer (PFE) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 46.88% and 3.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.

Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY

Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.

Pre-Markets in Green to Start a Crucial Week of Events

Pre-Markets in Green to Start a Crucial Week of Events.

Mark Vickery headshot

Busy Week for Earnings, Fed, Reports; MCD, ON Beat in Q3

Mid-October near-term highs have given way to lower trading levels for the most part in the past couple weeks.

The Zacks Analyst Blog Highlights Costco Wholesale, Pfizer, IBM, NextEra Energy and HCA Healthcare

Costco Wholesale, Pfizer, IBM, NextEra Energy and HCA Healthcare are part of the Zacks top Analyst Blog.

Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Mark Vickery headshot

Top Research Reports for Costco, Pfizer & IBM

Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp. (COST), Pfizer Inc. (PFE) and IBM Corp. (IBM).

Kinjel Shah headshot

Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products

Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh

AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 3.15% and 1.65%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $30.84, moving +0.62% from the previous trading session.

Charles River (CRL) Offers Access to Preclinical Cancer Research

Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View

J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights

Pfizer (PFE) concluded the recent trading session at $32.75, signifying a -1.56% move from its prior day's close.

Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View

Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.

Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day

Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day.

Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.56% and 1.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Pop on Bargain Hunting, Stronger Economy

The small-cap Russell 2000, still under water over the past month, led the way higher today.

Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA Nod

The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.

Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls

Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.